Annual CFO
-$72.53 M
+$11.55 M+13.74%
31 December 2023
Summary:
CymaBay Therapeutics annual cash flow from operations is currently -$72.53 million, with the most recent change of +$11.55 million (+13.74%) on 31 December 2023. During the last 3 years, it has fallen by -$3.10 million (-4.46%).CBAY Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$27.38 M
-$1.24 M-4.72%
31 December 2023
Summary:
CymaBay Therapeutics quarterly cash flow from operations is currently -$27.38 million, with the most recent change of -$1.24 million (-4.72%) on 31 December 2023.CBAY Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$72.53 M
-$8.62 M-13.49%
31 December 2023
Summary:
CymaBay Therapeutics TTM cash flow from operations is currently -$72.53 million, with the most recent change of -$8.62 million (-13.49%) on 31 December 2023.CBAY TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CBAY Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -4.5% | -92.2% | -4.5% |
| 5 y5 years | +25.9% | +2.7% | +25.9% |
CBAY Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | +757.5% | -525.8% | +3259.5% |
CymaBay Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | -$72.53 M(-13.7%) | -$27.38 M(+4.7%) | -$72.53 M(+13.5%) |
| Sept 2023 | - | -$26.14 M(+2.8%) | -$63.91 M(+15.6%) |
| June 2023 | - | -$25.44 M(-495.5%) | -$55.28 M(+5.7%) |
| Mar 2023 | - | $6.43 M(-134.3%) | -$52.29 M(-37.8%) |
| Dec 2022 | -$84.08 M(+21.1%) | -$18.76 M(+7.0%) | -$84.08 M(+5.7%) |
| Sept 2022 | - | -$17.52 M(-21.9%) | -$79.57 M(+2.7%) |
| June 2022 | - | -$22.44 M(-11.5%) | -$77.46 M(+4.3%) |
| Mar 2022 | - | -$25.36 M(+78.1%) | -$74.23 M(+6.9%) |
| Dec 2021 | -$69.43 M(+55.2%) | -$14.24 M(-7.6%) | -$69.43 M(-0.8%) |
| Sept 2021 | - | -$15.41 M(-19.8%) | -$70.00 M(+12.8%) |
| June 2021 | - | -$19.21 M(-6.6%) | -$62.04 M(+22.7%) |
| Mar 2021 | - | -$20.56 M(+38.8%) | -$50.58 M(+13.1%) |
| Dec 2020 | -$44.73 M(-54.3%) | -$14.82 M(+98.8%) | -$44.73 M(-22.9%) |
| Sept 2020 | - | -$7.45 M(-3.8%) | -$58.05 M(-21.3%) |
| June 2020 | - | -$7.75 M(-47.3%) | -$73.72 M(-18.3%) |
| Mar 2020 | - | -$14.71 M(-47.7%) | -$90.22 M(-7.8%) |
| Dec 2019 | -$97.91 M(+78.2%) | -$28.14 M(+21.7%) | -$97.91 M(+9.6%) |
| Sept 2019 | - | -$23.13 M(-4.6%) | -$89.37 M(+8.6%) |
| June 2019 | - | -$24.25 M(+8.3%) | -$82.32 M(+16.1%) |
| Mar 2019 | - | -$22.39 M(+14.3%) | -$70.89 M(+29.0%) |
| Dec 2018 | -$54.94 M | -$19.59 M(+21.9%) | -$54.94 M(+32.7%) |
| Sept 2018 | - | -$16.08 M(+25.4%) | -$41.41 M(+34.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2018 | - | -$12.82 M(+99.1%) | -$30.80 M(+29.0%) |
| Mar 2018 | - | -$6.44 M(+6.1%) | -$23.87 M(+21.6%) |
| Dec 2017 | -$19.63 M(-15.9%) | -$6.07 M(+11.1%) | -$19.63 M(+3.5%) |
| Sept 2017 | - | -$5.47 M(-7.2%) | -$18.96 M(-1.4%) |
| June 2017 | - | -$5.89 M(+167.4%) | -$19.24 M(-0.9%) |
| Mar 2017 | - | -$2.20 M(-59.2%) | -$19.42 M(-16.9%) |
| Dec 2016 | -$23.35 M(+0.1%) | -$5.40 M(-5.9%) | -$23.35 M(+0.9%) |
| Sept 2016 | - | -$5.74 M(-5.4%) | -$23.15 M(-3.8%) |
| June 2016 | - | -$6.07 M(-1.1%) | -$24.07 M(+3.3%) |
| Mar 2016 | - | -$6.14 M(+18.2%) | -$23.30 M(-0.1%) |
| Dec 2015 | -$23.32 M(+10.5%) | -$5.20 M(-22.0%) | -$23.32 M(-8.9%) |
| Sept 2015 | - | -$6.66 M(+25.4%) | -$25.60 M(+12.1%) |
| June 2015 | - | -$5.31 M(-13.8%) | -$22.83 M(+2.6%) |
| Mar 2015 | - | -$6.16 M(-17.6%) | -$22.26 M(+5.4%) |
| Dec 2014 | -$21.11 M(+149.6%) | -$7.47 M(+92.0%) | -$21.11 M(+22.9%) |
| Sept 2014 | - | -$3.89 M(-17.9%) | -$17.18 M(+23.7%) |
| June 2014 | - | -$4.74 M(-5.4%) | -$13.89 M(+22.8%) |
| Mar 2014 | - | -$5.01 M(+41.7%) | -$11.31 M(+33.7%) |
| Dec 2013 | -$8.46 M(-25.1%) | -$3.54 M(+488.5%) | -$8.46 M(+71.9%) |
| Sept 2013 | - | -$601.00 K(-72.2%) | -$4.92 M(+13.9%) |
| June 2013 | - | -$2.16 M(+0.1%) | -$4.32 M(+100.1%) |
| Mar 2013 | - | -$2.16 M | -$2.16 M |
| Dec 2012 | -$11.29 M | - | - |
FAQ
- What is CymaBay Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for CymaBay Therapeutics?
- What is CymaBay Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for CymaBay Therapeutics?
- What is CymaBay Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for CymaBay Therapeutics?
What is CymaBay Therapeutics annual cash flow from operations?
The current annual CFO of CBAY is -$72.53 M
What is the all time high annual CFO for CymaBay Therapeutics?
CymaBay Therapeutics all-time high annual cash flow from operations is -$8.46 M
What is CymaBay Therapeutics quarterly cash flow from operations?
The current quarterly CFO of CBAY is -$27.38 M
What is the all time high quarterly CFO for CymaBay Therapeutics?
CymaBay Therapeutics all-time high quarterly cash flow from operations is $6.43 M
What is CymaBay Therapeutics TTM cash flow from operations?
The current TTM CFO of CBAY is -$72.53 M
What is the all time high TTM CFO for CymaBay Therapeutics?
CymaBay Therapeutics all-time high TTM cash flow from operations is -$2.16 M